Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain - PubMed (original) (raw)

Review

Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain

Elizabeth C M de Lange et al. Clin Pharmacokinet. 2002.

Abstract

In the clinical setting, drug concentrations in cerebrospinal fluid (CSF) are sometimes used as a surrogate for drug concentrations at the target site within the brain. However, the brain consists of multiple compartments and many factors are involved in the transport of drugs from plasma into the brain and the distribution within the brain. In particular, active transport processes at the level of the blood-brain barrier and blood-CSF barrier, such as those mediated by P-glycoprotein, may lead to complex relationships between concentrations in plasma, ventricular and lumbar CSF, and other brain compartments. Therefore, CSF concentrations may be difficult to interpret and may have limited value. Pharmacokinetic data obtained by intracerebral microdialysis monitoring may be used instead, providing more valuable information. As non-invasive alternative techniques, positron emission tomography or magnetic resonance spectroscopy may be of added value.

PubMed Disclaimer

Similar articles

• Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier.
  de Lange EC, Danhof M, de Boer AG, Breimer DD. de Lange EC, et al. Brain Res Brain Res Rev. 1997 Sep 30;25(1):27-49. doi: 10.1016/s0165-0173(97)00014-3. Brain Res Brain Res Rev. 1997. PMID: 9370049 Review.
• CSF as a surrogate for assessing CNS exposure: an industrial perspective.
  Lin JH. Lin JH. Curr Drug Metab. 2008 Jan;9(1):46-59. doi: 10.2174/138920008783331077. Curr Drug Metab. 2008. PMID: 18220571 Review.
• Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
  Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M. Fridén M, et al. J Med Chem. 2009 Oct 22;52(20):6233-43. doi: 10.1021/jm901036q. J Med Chem. 2009. PMID: 19764786
• Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
  Nagaya Y, Nozaki Y, Takenaka O, Watari R, Kusano K, Yoshimura T, Kusuhara H. Nagaya Y, et al. Drug Metab Pharmacokinet. 2016 Feb;31(1):57-66. doi: 10.1016/j.dmpk.2015.10.003. Epub 2015 Nov 5. Drug Metab Pharmacokinet. 2016. PMID: 26830080
• Utility of CSF in translational neuroscience.
  de Lange EC. de Lange EC. J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):315-26. doi: 10.1007/s10928-013-9301-9. Epub 2013 Feb 12. J Pharmacokinet Pharmacodyn. 2013. PMID: 23400635 Free PMC article. Review.

Cited by

• Penetration of colistin into cerebrospinal fluid.
  Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S, Alamanos I, Dimopoulou E, Baltopoulos G. Markantonis SL, et al. Antimicrob Agents Chemother. 2009 Nov;53(11):4907-10. doi: 10.1128/AAC.00345-09. Epub 2009 Aug 24. Antimicrob Agents Chemother. 2009. PMID: 19704130 Free PMC article.
• Understanding Drug Delivery to the Brain Using Liposome-Based Strategies: Studies that Provide Mechanistic Insights Are Essential.
  Juhairiyah F, de Lange ECM. Juhairiyah F, et al. AAPS J. 2021 Oct 28;23(6):114. doi: 10.1208/s12248-021-00648-z. AAPS J. 2021. PMID: 34713363 Free PMC article. Review.
• Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
  Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Agarwal S, et al. Expert Rev Mol Med. 2011 May 13;13:e17. doi: 10.1017/S1462399411001888. Expert Rev Mol Med. 2011. PMID: 21676290 Free PMC article. Review.
• Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.
  Clinckers R, Smolders I, Michotte Y, Ebinger G, Danhof M, Voskuyl RA, Della Pasqua O. Clinckers R, et al. Br J Pharmacol. 2008 Dec;155(7):1127-38. doi: 10.1038/bjp.2008.366. Epub 2008 Oct 6. Br J Pharmacol. 2008. PMID: 18836479 Free PMC article.
• Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.
  Danhof M. Danhof M. J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):447-62. doi: 10.1007/s10928-015-9437-x. Epub 2015 Aug 30. J Pharmacokinet Pharmacodyn. 2015. PMID: 26319673 Free PMC article.

References

1. 1. Brain Res. 1977 May 27;127(2):251-67 - PubMed
2. 1. J Pharmacokinet Biopharm. 1994 Jun;22(3):207-27 - PubMed
3. 1. Clin Pharmacokinet. 1992 Sep;23(3):191-215 - PubMed
4. 1. Psychopharmacology (Berl). 1997 May;131(1):19-22 - PubMed
5. 1. J Pharmacol Exp Ther. 1998 Mar;284(3):1095-103 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program